Design, synthesis and structure-activity studies of rhodanine derivatives as HIV-1 integrase inhibitors

Molecules

Volumn 15, Issue 6, 2010, Pages 3958-3992

  Ramkumar, Kavya ^a   Yarovenko, Vladimir N ^b   Nikitina, Alexandra S ^c   Zavarzin, Igor V ^b   Krayushkin, Mikhail M ^b   Kovalenko, Leonid V ^c   Esqueda, Adrian ^a   Odde, Srinivas ^a   Neamati, Nouri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b N D ZELINSKY INSTITUTE OF ORGANIC CHEMISTRY   (Russian Federation)

^c MENDELEEV UNIVERSITY OF CHEMICAL TECHNOLOGY OF RUSSIA   (Russian Federation)

Author keywords

2 thioxo 4 thiazolidinone; APE1; Docking; HIV 1; Integrase; Rhodanine

Indexed keywords

APEX1 PROTEIN, HUMAN; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; INTEGRASE INHIBITOR; RHODANINE;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; HUMAN; SYNTHESIS; ANTAGONISTS AND INHIBITORS;

DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; HIV INTEGRASE INHIBITORS; HUMANS; MOLECULAR STRUCTURE; RHODANINE;

EID: 77954296650     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules15063958     Document Type: Article

References (41)

1. Hicks, C.; Gulick, R. M. Raltegravir: the first HIV type 1 integrase inhibitor. Clin. Infect. Dis. 2009, 48, 931-939.
2. Ramkumar, K.; Neamati, N. Raltegravir: The evidence of its therapeutic value in HIV-1 infection. Core Evidence 2009, 4, 131-147.
3. Bushman, F. D.; Craigie, R. Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. Proc. Natl. Acad. Sci. USA 1991, 88, 1339-1343.
4. Craigie, R. HIV integrase, a brief overview from chemistry to therapeutics. J. Biol. Chem. 2001, 276, 23213-23216.
5. Vandegraaff, N.; Engelman, A. Molecular mechanisms of HIV integration and therapeutic intervention. Expert Rev. Mol. Med. 2007, 9, 1-19.
6. Serrao, E.; Odde, S.; Ramkumar, K.; Neamati, N. Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology 2009, 6, 25-49.
7. Dayam, R.; Gundla, R.; Al-Mawsawi, L. Q.; Neamati, N. HIV-1 integrase inhibitors: 2005-2006 update. Med. Res. Rev. 2008, 28, 118-154. (Pubitemid 350274962)
8. Nair, V.; Chi, G. HIV integrase inhibitors as therapeutic agents in AIDS. Rev. Med. Virol. 2007, 17, 277-295.
9. Sechi, M.; Bacchi, A.; Carcelli, M.; Compari, C.; Duce, E.; Fisicaro, E.; Rogolino, D.; Gates, P.; Derudas, M.; Al-Mawsawi, L. Q.; Neamati, N. From ligand to complexes: inhibition of human immunodeficiency virus type 1 integrase by beta-diketo acid metal complexes. J. Med. Chem. 2006, 49, 4248-4260.
10. Zhao, G.; Wang, C.; Liu, C.; Lou, H. New developments in diketo-containing inhibitors of HIV-1 integrase. Mini Rev. Med. Chem. 2007, 7, 707-725.
11. Dayam, R.; Al-Mawsawi, L. Q.; Zawahir, Z.; Witvrouw, M.; Debyser, Z.; Neamati, N. Quinolone 3-carboxylic acid pharmacophore: design of second generation HIV-1 integrase inhibitors. J. Med. Chem. 2008, 51, 1136-1144.
12. Dayam, R.; Sanchez, T.; Neamati, N. Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase. J. Med. Chem. 2005, 48, 8009-8015. (Pubitemid 41798431)
13. Deng, J.; Dayam, R.; Al-Mawsawi, L. Q.; Neamati, N. Design of second generation HIV-1 integrase inhibitors. Curr. Pharm. Des. 2007, 13, 129-141. (Pubitemid 46085288)
14. Dayam, R.; Sanchez, T.; Clement, O.; Shoemaker, R.; Sei, S.; Neamati, N. Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors. J. Med. Chem. 2005, 48, 111-120.
15. Nicklaus, M. C.; Neamati, N.; Hong, H.; Mazumder, A.; Sunder, S.; Chen, J.; Milne, G. W.; Pommier, Y. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J. Med. Chem. 1997, 40, 920-929. (Pubitemid 27131621)
16. Johnson, S. L.; Chen, L. H.; Harbach, R.; Sabet, M.; Savinov, A.; Cotton, N. J.; Strongin, A.; Guiney, D.; Pellecchia, M. Rhodanine derivatives as selective protease inhibitors against bacterial toxins. Chem. Biol. Drug Des. 2008, 71, 131-139.
17. Cutshall, N. S.; O'Day, C.; Prezhdo, M. Rhodanine derivatives as inhibitors of JSP-1. Bioorg. Med. Chem. Lett. 2005, 15, 3374-3379.
18. Irvine, M. W.; Patrick, G. L.; Kewney, J.; Hastings, S. F.; MacKenzie, S. J. Rhodanine derivatives as novel inhibitors of PDE4. Bioorg. Med. Chem. Lett. 2008, 18, 2032-2037.
19. Sing, W. T.; Lee, C. L.; Yeo, S. L.; Lim, S. P.; Sim, M. M. Arylalkylidene rhodanine with bulky and hydrophobic functional group as selective HCV NS3 protease inhibitor. Bioorg. Med. Chem. Lett. 2001, 11, 91-94.
20. Kawakami, M.; Koya, K.; Ukai, T.; Tatsuta, N.; Ikegawa, A.; Ogawa, K.; Shishido, T.; Chen, L. B. Structure-activity of novel rhodacyanine dyes as antitumor agents. J. Med. Chem. 1998, 41, 130-142.
21. Villain-Guillot, P.; Gualtieri, M.; Bastide, L.; Roquet, F.; Martinez, J.; Amblard, M.; Pugniere, M.; Leonetti, J. P. Structure-activity relationships of phenyl-furanyl-rhodanines as inhibitors of RNA polymerase with antibacterial activity on biofilms. J. Med. Chem. 2007, 50, 4195-4204.
22. Tomasic, T.; Masic, L. P. Rhodanine as a Privileged Scaffold in Drug Discovery Curr. Med. Chem. 2009, 16, 1596-1629.
23. Yarovenko, V. N.; Nikitina, A. S.; Zavarzin, I. V.; Krayushkin, M. M.; Kovalenko, L. V. A convenient synthesis of N-substituted 2-thioxo-1, 3-thiazolidin-4-ones. Synthesis 2006, 8, 1246-1248.
24. Fishel, M. L.; Kelley, M. R. The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol. Aspects Med. 2007, 28, 375-395.
25. Luo, M.; Delaplane, S.; Jiang, A.; Reed, A.; He, Y.; Fishel, M.; Nyland, R. L. 2nd; Borch, R. F.; Qiao, X.; Georgiadis, M. M.; Kelley, M. R. Role of the multifunctional DNA repair and redox signaling protein Ape1/Ref-1 in cancer and endothelial cells: small-molecule inhibition of the redox function of Ape1. Antioxid. Redox Signal. 2008, 10, 1853-1867.
26. Zawahir, Z.; Dayam, R.; Deng, J.; Pereira, C.; Neamati, N. Pharmacophore guided discovery of small-molecule human apurinic/apyrimidinic endonuclease 1 inhibitors. J. Med. Chem. 2009, 52, 20-32.
27. Lipinski, C. A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 2000, 44, 235-249.
28. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46, 3-26. (Pubitemid 33653411)
29. Egan, W. J.; Lauri, G. Prediction of intestinal permeability. Adv. Drug Deliv. Rev. 2002, 54, 273-289.
30. Egan, W. J.; Merz, K. M., Jr.; Baldwin, J. J. Prediction of drug absorption using multivariate statistics. J. Med. Chem. 2000, 43, 3867-3877.
31. Palm, K.; Luthman, K.; Ungell, A. L.; Strandlund, G.; Artursson, P. Correlation of drug absorption with molecular surface properties. J. Pharm. Sci. 1996, 85, 32-39.
32. Palm, K.; Luthman, K.; Ungell, A. L.; Strandlund, G.; Beigi, F.; Lundahl, P.; Artursson, P. Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors. J. Med. Chem. 1998, 41, 5382-5392.
33. Palm, K.; Stenberg, P.; Luthman, K.; Artursson, P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 1997, 14, 568-571.
34. Kelder, J.; Grootenhuis, P. D.; Bayada, D. M.; Delbressine, L. P.; Ploemen, J. P. Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs. Pharm. Res. 1999, 16, 1514-1519.
35. Catalyst 4.11; Accelrys Inc.: San Diego, CA, USA, 2005. 36. GOLD 3.2; CCDC: Cambridge, UK, 2002.
36. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 2004, 47, 1739-1749.
37. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem. 2004, 47, 1750-1759.
38. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput. Aided Mol. Des. 1997, 11, 425-445.
39. ADMET Predictor 3.0; Simulations Plus, Inc.: Lancaster, CA, USA, 2008.
40. Grande, F.; Aiello, F.; Grazia, O. D.; Brizzi, A.; Garofalo, A.; Neamati, N. Synthesis and antitumor activities of a series of novel quinoxalinhydrazides. Bioorg. Med. Chem. 2007, 15, 288-294.
41. Plasencia, C.; Dayam, R.; Wang, Q.; Pinski, J.; Burke, T. R., Jr.; Quinn, D. I.; Neamati, N. Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormonedependent and-independent cancer cell lines. Mol. Cancer Ther. 2005, 4, 1105-1113.